- Sandi Alexander Kwee, MD, PhD
- Associate Professor, Clinical and Translational Sciences Program, University of Hawaii Cancer Center, and John A. Burns School of Medicine, University of Hawaii, Honolulu, USA.
Website | E-mail
Special Issue Introduction
Immune checkpoint inhibitor agents are now used for the treatment of hepatocellular carcinoma (HCC) in many parts of the world. However, objective responses to these agents occur in only a small fraction of patients, and a reliable tissue, serum, or imaging biomarker for predicting therapeutic response has yet to be identified. The pathways and mechanisms underlying the development of immunotherapy resistance are also poorly understood, and clinically, there is still a need to further define the role of biomarkers for immune checkpoint inhibitors used alone or in combination with other therapies. For this special issue on immunotherapy and immunotherapy biomarkers in HCC, we invite original articles, perspectives, and reviews that support the goal of improving HCC immunotherapy effectiveness and precision through clinical and pre-clinical research.
Participants1. Sandi Alexander Kwee Departments of Medicine and Surgery, John A. Burns School of Medicine, University of Hawaii, Honolulu, USA.
2. Zuzana Macek Jilkova Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France.
3. Thomas Decaens Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France.
4. Aiwu Ruth He Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
5. Samantha A. Armstrong Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
6. Manny D. Bacolod Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, 10065, USA.
7. Jun Liu Departments of Clinical Lab, Yue Bei Peoples Hospital, Shaoguan, China.
8. Esther Una Cidon Department of Medical Oncology, Royal Bournemouth and Christchurch Hospital NHS Foundation Trust, Bournemouth, UK.
9. Ming Shi School of Life Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang Province, China.
10. Michael Heneghan Institute of Liver Studies, King's College Hospital, London, UK.
11. Smruti Ranjan Mohanty Division of Gastroenterology and Hepatobiliary Diseases, New York-Presbyterian Brooklyn Methodist Hospital, NY, USA.
12. Deng-Fu Yao Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
13. Flavia Feier Hepatology and Liver Transplantation, Hospital Sirio Libanes, São Paulo, Brazil.
14. Hong-Ping Xia State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China.
15. Tao Peng Hepatobiliary Surgery Department, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
16. James Kuo Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
17. Chang-Qing Xie Center for Cancer Research, National Cancer Institute, Bethesda,USA.
18. Martina Gambato Department of Surgery, Padua University Hospital, Padua, Italy.
19. Brian Irving Carr Department of Surgery, Liver Transplantation Institute, Inonu University, Malatya, Turkey.
The list is arranged in no particular order and being updated.
Submission Deadline15 Sep 2020